CORRECTED: Crescendo Bioscience Announces Four Poster Presentations at the American College of Rheumatology 2016 Annual Meeti...
October 03 2016 - 4:20PM
Note: the titles and abstract numbers have been corrected.
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics,
Inc. (NASDAQ:MYGN), today announced that four poster presentations
on Vectra® DA will be featured at the American College of
Rheumatology (ACR) meeting being held Nov. 11-16, 2016 in
Washington, D.C. Vectra DA is the first and only
multi-biomarker blood test validated to measure disease activity in
patients with RA and has been evaluated in multiple clinical
studies.
Please plan to visit Crescendo at Booth #323 for
information about Vectra DA. Abstracts are available online
at:
http://acrabstracts.org/meetings/2016-acrarhp-annual-meeting/.
Below is a list of the highlighted Crescendo Bioscience
presentations at ACR (#ACR16):
Poster Presentations
- Title: Predicting Flare and Sustained Clinical
Remission After Adalimumab Withdrawal Using the Multi-Biomarker
Disease Activity (MBDA) Score.Presenter: Shintaro
Hirata.Date: Tuesday, Nov. 15, 2016: 9:00-11:00
a.m. ET.Abstract: 2639.
- Title:. Multi-Biomarker Disease Activity
(MBDA) Score and Prediction of Radiographic Progression in a
Randomized Study of Patients with Early RA Treated with
Methotrexate Alone or with Adalimumab.Presenter:
Heegaard Brahe.Date: Tuesday, Nov. 15, 2016:
9:00-11:00 a.m. ET.Abstract: 2520.
- Title: Examination of Diurnal and Daily
Variation of the Multi-Biomarker Disease Activity (MBDA) Score in
RA to Establish a Minimally Important
Difference.Presenter: David
Chernoff.Date: Sunday, Nov. 13, 2016: 9:00-11:00
a.m. ET.Abstract: 535.
- Title: Biomarker-Related Risk for Myocardial
Infarction and Serious Infections in Patients with Rheumatoid
Arthritis: A Population-Based Study.Presenter:
Jeff Curtis.Date: Monday, Nov. 14, 2016:
9:00-11:00 a.m. ET.Abstract: 1492.
About Rheumatoid
ArthritisRheumatoid arthritis is a chronic, systemic
inflammatory condition that is often characterized by symptoms that
include pain, stiffness and inflammation of the joints, and in some
cases, joint destruction and disability. An estimated 1.5
million Americans have the condition, which affects nearly
three times as many women as men. While the cause of RA is unknown,
many cases are believed to result from genetic and environmental
factors.
About Vectra® DA Vectra DA is the
only multi-biomarker blood test for rheumatoid arthritis disease
activity that integrates the concentrations of 12 serum proteins
associated with RA disease activity into a single objective score,
on a scale of 1 to 100, to help physicians make more informed
treatment decisions. Vectra DA testing is performed at the
Crescendo Bioscience state-of-the-art CLIA (Clinical Laboratory
Improvement Amendments) facility. Test results are reported to the
physician 5 to 7 days from shipping of the specimen to Crescendo
Bioscience. Physicians can receive test results via standard mail,
by fax or via the private web portal, VectraView. For more
information on Vectra DA, please visit: www.Vectra-DA.com.
About Crescendo
BioscienceCrescendo Bioscience, a wholly-owned subsidiary
of Myriad Genetics, Inc., is a molecular diagnostics company
dedicated to developing and commercializing quantitative blood
tests for rheumatoid arthritis (RA) and other autoimmune diseases,
located in South San Francisco, Calif. Crescendo Bioscience
develops quantitative, objective, reproducible blood tests to
provide rheumatologists with deeper clinical insight to help enable
more effective management of patients with autoimmune and
inflammatory diseases. For more information, please visit the
company website at www.CrescendoBio.com.
About Myriad GeneticsMyriad
Genetics Inc., is a leading personalized medicine company dedicated
to being a trusted advisor transforming patient lives worldwide
with pioneering molecular diagnostics. Myriad discovers and
commercializes molecular diagnostic tests that: determine the risk
of developing disease, accurately diagnose disease, assess the risk
of disease progression, and guide treatment decisions across six
major medical specialties where molecular diagnostics can
significantly improve patient care and lower healthcare
costs. Myriad is focused on three strategic imperatives:
transitioning and expanding its hereditary cancer testing markets,
diversifying its product portfolio through the introduction of new
products and increasing the revenue contribution from international
markets. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis,
Colaris, Colaris AP, EndoPredict, myPath, myRisk, Myriad myRisk,
myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor
BRACAnalysis CDx, myChoice HRD, Vectra, Prolaris and GeneSight are
trademarks or registered trademarks of Myriad Genetics, Inc. or its
wholly owned subsidiaries in the United States and foreign
countries. MYGN-F, MYGN-G
Safe Harbor StatementThis press
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
statements relating to the Vectra DA data to be presented at the
2016 American College of Rheumatology (ACR) Annual Meeting, Nov.
11-16, 2016 in Washington, D.C.; and the Company’s strategic
directives under the caption “About Myriad Genetics.” These
“forward-looking statements” are based on management’s current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those described or implied in the
forward-looking statements. These risks and uncertainties include,
but are not limited to: the risk that sales and profit margins of
our existing molecular diagnostic tests and pharmaceutical and
clinical services may decline or will not continue to increase at
historical rates; risks related to our ability to transition from
our existing product portfolio to our new tests, including
unexpected costs and delays; risks related to changes in the
governmental or private insurers’ reimbursement levels for our
tests or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services tests and any future tests are terminated or
cannot be maintained on satisfactory terms; risks related to delays
or other problems with operating our laboratory testing facilities;
risks related to public concern over our genetic testing in general
or our tests in particular; risks related to regulatory
requirements or enforcement in the United States and foreign
countries and changes in the structure of the healthcare system or
healthcare payment systems; risks related to our ability to obtain
new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire, including but not limited to our acquisition of a
healthcare clinic in Germany and Sividon Diagnostic and our planned
acquisition of Assurex Health; risks related to our projections
about our business, results of operations and financial condition;
risks related to the potential market opportunity for our products;
the risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents; risks related to changes in
intellectual property laws covering our molecular diagnostic tests
and pharmaceutical and clinical services and patents or enforcement
in the United States and foreign countries, such as the Supreme
Court decision in the lawsuit brought against us by the Association
for Molecular Pathology et al; risks of new, changing and
competitive technologies and regulations in the United States and
internationally; and other factors discussed under the heading
“Risk Factors” contained in Item 1A of our Annual report on Form
10-K for the fiscal year ended June 30, 2016, which has been filed
with the Securities and Exchange Commission, as well as any updates
to those risk factors filed from time to time in our Quarterly
Reports on Form 10-Q or Current Reports on Form 8-K.
Media Contact: Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact: Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024